MARGINPROBE®

Proven to reduce re-excisions in breast cancer





MarginProbe® Radiofrequency

Spectroscopy System

Identifies, in real-time, positive margins by detecting microscopic residual cancer and DCIS at the surface of excised breast tissue, enabling immediate action by the surgeon, thereby reducing the need for re-excision surgery.

Did I get it all?

Current margin assessment methods cannot fully address need



- Cannot palpate/visualize microscopic invasive cancer nor DCIS
- Low sensitivity for ILC

Frozen Section

- Difficult due to fatty nature of breast tissue
- May add significant time to procedure

Full Cavity Shave

- Can compromise cosmetic outcomes due to volume of healthy tissue removed
- Thinner shaves to manage tissue volume can result in reduced success clearing final margins

Re-excision impacts everyone



DTS

- Increased financial burden
- Increased complications
- Delays adjuvant treatment
- Poor cosmesis



roviders


- Disappointment of telling patient
 "I didn't get it all"
- Decreased patient satisfaction
- Compromises IORT and oncoplastic procedures




ayers

- Tremendous cost to healthcare system
- Average \$16k/procedure¹
- Not aligned with shift from volume to value

How does MarginProbe® work?




Real-time assessment and binary results with no disruption to surgical workflow



Growing body of evidence

Proving substantial clinical effectiveness



MarginProbe®. Do it once. Get it all.

